Reducing residual thrombotic risk in patients with peripheral artery disease: impact of the COMPASS trial

Reducing residual thrombotic risk in patients with peripheral artery disease: impact of the COMPASS trial

Patients with peripheral artery disease (PAD) are at a high risk not only for the classical cardiovascular (CV) outcomes (major adverse cardiovascular events; MACE) but also for vascular limb events (major adverse limb events; MALE). Therefore, a comprehensive approach for these patients should incl...

Full description

Bibliographic Details
Main Authors: José Luis Hernández, Francisco S Lozano, Vincent Riambau, Manuel Almendro-Delia, Juan Cosín-Sales, Sergi Bellmunt-Montoya, Javier Garcia-Alegria, Xavier Garcia-Moll, Juan José Gomez-Doblas, José R Gonzalez-Juanatey, Carmen Suarez Fernández
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2020-07-01
Series:Drugs in Context
Subjects:
compass
peripheral artery disease
residual risk
rivaroxaban
Online Access:https://www.drugsincontext.com/reducing-residual-thrombotic-risk-in-patients-with-peripheral-artery-disease:-impact-of-the-compass-trial

Internet

https://www.drugsincontext.com/reducing-residual-thrombotic-risk-in-patients-with-peripheral-artery-disease:-impact-of-the-compass-trial

Similar Items